Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma

AIM: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). PATIENTS & METHODS: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI) from January 2016 to January 2017. Primary en...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CNS Oncol
Main Authors: Modelevsky, Lisa, Tizon, Richard, Reiss, Samantha N, Smith, Marcel, Garonce, Rachel, Kaley, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6200062/
https://ncbi.nlm.nih.gov/pubmed/30221993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2018-0001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados